Medical therapy of HCC
- PMID: 34538616
- DOI: 10.1016/j.jhep.2021.05.017
Medical therapy of HCC
Keywords: VEGF; hepatocellular carcinoma; immunotherapy; molecular therapy; targeted therapies; tyrosine kinase inhibitor.
Conflict of interest statement
Conflict of Interest Honoraria for Speaker, consultancy and advisory role to AV: Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Ipsen, PierreFabre, MSD. Honoraria for Speaker, consultancy and advisory role to AS: Roche, BMS and Servier. Please refer to the accompanying ICMJE disclosure forms for further details.